Royalty Pharma
Buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry.
Market cap
$15.1b
Enterprise value
$20.9b
Share price
$36.03 RPRX
Recent deals
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | $1.5b | Post IPO Debt |
| Total Funding | 000k | ||
Quadrille Capital(exited)
General Atlantic(exited)
Archimedia Investments(exited)
Ascendis Pharma(exited)
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 8 % | (2 %) | 5 % | (4 %) | 36 % | 6 % | 8 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 65 % | 44 % | 67 % | 60 % | 91 % | 94 % | 95 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 27 % | 2 % | 48 % | 38 % | 23 % | 39 % | 45 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 9 % | 8 % | 2 % | - | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Royalty Pharma
Editexited
exited
exited
ACQUISITION by Sanofi Jun 2025
exited
ACQUISITION by Ipsen Jun 2022
ACQUISITION by Pfizer Oct 2022
ACQUISITION by Royalty Pharma May 2012
